Ani Pharmaceuticals Inc ANIP
We take great care to ensure that the data presented and summarized in this overview for ANI PHARMACEUTICALS INC is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding ANIP
View all-
Black Rock Inc. New York, NY2.66MShares$148 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.35MShares$75.1 Million0.0% of portfolio
-
Goldman Sachs Group Inc New York, NY716KShares$39.9 Million0.01% of portfolio
-
State Street Corp Boston, MA704KShares$39.2 Million0.0% of portfolio
-
Dimensional Fund Advisors LP Austin, TX655KShares$36.5 Million0.01% of portfolio
-
Ranger Investment Management, L.P. Dallas, TX590KShares$32.8 Million2.32% of portfolio
-
Pacer Advisors, Inc. Malvern, PA568KShares$31.7 Million0.08% of portfolio
-
Jpmorgan Chase & CO New York, NY555KShares$30.9 Million0.0% of portfolio
-
Global Alpha Capital Management Ltd.536KShares$29.9 Million2.08% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il530KShares$29.5 Million0.01% of portfolio
Latest Institutional Activity in ANIP
Top Purchases
Top Sells
About ANIP
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncology products, hormones and steroids, injectables, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; and potent products, as well as performs contract development and manufacturing of pharmaceutical products for other companies. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, and group purchasing organizations. The company was incorporated in 2001 and is headquartered in Baudette, Minnesota.
Insider Transactions at ANIP
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 15
2024
|
Thomas Andrew Rowland SVP, HEAD - ESTABLISHED BRANDS |
SELL
Payment of exercise price or tax liability
|
Direct |
867
-2.55%
|
$48,552
$56.58 P/Share
|
|
Nov 15
2024
|
Christopher Mutz HEAD OF RARE DISEASE |
SELL
Open market or private sale
|
Direct |
6,500
-7.81%
|
$370,500
$57.7 P/Share
|
|
Nov 13
2024
|
Meredith Cook SR. VP, GENERAL COUNSEL & SEC. |
SELL
Open market or private sale
|
Direct |
250
-0.44%
|
$15,250
$61.36 P/Share
|
|
Oct 14
2024
|
Meredith Cook SR. VP, GENERAL COUNSEL & SEC. |
SELL
Open market or private sale
|
Direct |
250
-0.44%
|
$14,250
$57.19 P/Share
|
|
Sep 13
2024
|
Meredith Cook SR. VP, GENERAL COUNSEL & SEC. |
SELL
Open market or private sale
|
Direct |
250
-0.44%
|
$14,000
$56.82 P/Share
|
|
Sep 12
2024
|
Krista Davis SVP, CHIEF HR OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
1,486
-2.88%
|
$83,216
$56.15 P/Share
|
|
Sep 08
2024
|
Nikhil Lalwani PRESIDENT & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
3,646
-0.97%
|
$218,760
$60.51 P/Share
|
|
Aug 13
2024
|
Meredith Cook SR. VP, GENERAL COUNSEL & SEC. |
SELL
Open market or private sale
|
Direct |
250
-0.44%
|
$14,750
$59.62 P/Share
|
|
Jul 18
2024
|
Muthusamy Shanmugam HEAD OF R&D, COO-NOVITIUM OPS |
SELL
Open market or private sale
|
Indirect |
2,743
-0.43%
|
$170,066
$62.0 P/Share
|
|
Jul 18
2024
|
Meredith Cook SR. VP, GENERAL COUNSEL & SEC. |
SELL
Payment of exercise price or tax liability
|
Direct |
1,743
-2.96%
|
$106,323
$61.35 P/Share
|
|
Jul 17
2024
|
Muthusamy Shanmugam HEAD OF R&D, COO-NOVITIUM OPS |
SELL
Open market or private sale
|
Indirect |
14,257
-2.19%
|
$898,191
$63.16 P/Share
|
|
Jul 16
2024
|
Muthusamy Shanmugam HEAD OF R&D, COO-NOVITIUM OPS |
SELL
Open market or private sale
|
Indirect |
22,000
-3.28%
|
$1,408,000
$64.27 P/Share
|
|
Jul 15
2024
|
Muthusamy Shanmugam HEAD OF R&D, COO-NOVITIUM OPS |
SELL
Open market or private sale
|
Indirect |
11,000
-1.61%
|
$693,000
$63.38 P/Share
|
|
Jul 12
2024
|
Meredith Cook SR. VP, GENERAL COUNSEL & SEC. |
SELL
Open market or private sale
|
Direct |
250
-0.42%
|
$16,000
$64.91 P/Share
|
|
Jul 01
2024
|
Chad Gassert SVP - CORP. DEV. & STRATEGY |
SELL
Open market or private sale
|
Indirect |
20,000
-9.38%
|
$1,260,000
$63.44 P/Share
|
|
Jun 21
2024
|
Muthusamy Shanmugam HEAD OF R&D, COO-NOVITIUM OPS |
SELL
Open market or private sale
|
Indirect |
20,000
-2.85%
|
$1,160,000
$58.9 P/Share
|
|
Jun 20
2024
|
Muthusamy Shanmugam HEAD OF R&D, COO-NOVITIUM OPS |
SELL
Open market or private sale
|
Indirect |
11,447
-1.6%
|
$675,373
$59.86 P/Share
|
|
Jun 18
2024
|
Muthusamy Shanmugam HEAD OF R&D, COO-NOVITIUM OPS |
SELL
Open market or private sale
|
Indirect |
10,607
-1.46%
|
$636,420
$60.76 P/Share
|
|
Jun 17
2024
|
Muthusamy Shanmugam HEAD OF R&D, COO-NOVITIUM OPS |
SELL
Open market or private sale
|
Indirect |
7,946
-1.08%
|
$484,706
$61.41 P/Share
|
|
Jun 13
2024
|
Meredith Cook SR. VP, GENERAL COUNSEL & SEC. |
SELL
Open market or private sale
|
Direct |
250
-0.42%
|
$15,750
$63.8 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 359K shares |
|---|---|
| Exercise of conversion of derivative security | 12.6K shares |
| Payment of exercise price or tax liability | 105K shares |
|---|---|
| Open market or private sale | 578K shares |